Roy A. Whitfield
Lead Independent DirectorMr. Roy A. Whitfield served as the Chief Executive Officer of Hexagen PLC. Mr. Whitfield has management and governance experience in the biotechnology industry. He co-founded Incyte Corp., (formerly, Incyte Genomics, Inc.) in 1991 and served as its Chairman of the Board from November 2001 to June 24, 2003, Chief Executive Officer from June 1993 to November 2001, President from June 1991 to January 1997 and Treasurer from April 1991 to October 1995. At Incyte, he executed the first genomics initial public offering (IPO) and later raised over $700 million in financing. Mr. Whitfield served as President of Ideon Corporation from October 1989 to April 1991. From 1984 to 1989, he served Senior Operating and Business Development positions at Technicon Instruments Corporation and its predecessor company, Cooper Biomedical, Inc. At Technicon Instruments Cop., he spent seven years with Boston Consulting Group's international consulting practice. He serves as an Executive Chairman of BioSeek, Inc. He served as Chairman of Science and Business Advisory Board of Sciona, Inc., since June 2005. Mr. Whitfield has been a Director of BioSeek, Inc. since February 6, 2006. He has been an Independent Director at Nektar Therapeutics since August 2000 and has been its Lead Director since January 2019. He serves as a Director of Station-X, Inc., Illumina, Inc., and Inhale Therapeutics Inc. He served as a Member of the Scientific Advisory Board at Sciona, Inc., since June 2005. He served as a Director of Solexa Inc. since August 2006; Sciona, Inc., since June 2005 and Incyte Corporation from 1991 to January 2014. He served as a Director of Aurora Biosciences Corp. since September 1997. He served as an Independent Director at Illumina Inc. since January 26, 2007 until May 29, 2017. He served as a Director of Iconix Biosciences, Inc. (formerly, Iconix Pharmaceuticals Inc.), DiscoveRx Corporation, Biotechnology Industry Organization and Hexagen PLC. Mr. Whitfield served as a Member of Advisory Committee of InterWest Partners. He received the 1997 Northern California Entrepreneur of the Year Award for Life Sciences and the 1996 Best of Biotech Award for Most Creative and Significant Strategic Alliances. Mr. Whitfield holds a B.S. Degree with First Class Honors in Mathematics from Oxford University and an M.B.A. with Distinction, from Stanford University.
Positions
- Company NameNektar TherapeuticsStock CodeNKTRPositionLead Independent DirectorColleagues
- HWHoward W. RobinCEO, President & Director
- RBRobert B. ChessIndependent Chairman of the Board
- JZJonathan ZalevskySenior VP and Chief Research & Development Officer
- LMLinda M. RubinsteinCFO and Principal Financial & Accounting Officer
- JBJason BarnardChief Accounting Officer
- EZElizabeth ZhangVP of Legal, Corporate Counsel & Secretary
- RSR. Scott GreerIndependent Director
- DMDiana M. BrainardIndependent Director
